|Articles|January 27, 2017
Aurinia Selects Worldwide for Phase III Lupus Trial
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study.
Advertisement
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
2
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
3
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
4
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
5